Literature DB >> 6289174

Are presynaptic dopamine autoreceptors and postsynaptic dopamine receptors in the rabbit caudate nucleus pharmacologically different?

I Helmreich, W Reimann, G Hertting, K Starke.   

Abstract

Slices of the rabbit caudate nucleus were preincubated with [3H]dopamine or [3H]choline and then superfused and stimulated electrically. Apomorphine reduced the stimulation-evoked overflow of tritium over the same concentration range, independently of whether slices had been pre-incubated with [3H]dopamine or with [3H]choline. Each of three antagonists--molindone, sulpiride and metoclopramide--increased the evoked overflow of tritium over the same concentration range in experiments with [3H]dopamine and those with [3H]choline. For each antagonist, the pA2 values against apomorphine obtained in [3H]dopamine experiments and in [3H]choline experiments were very similar. This study is a functional in vitro approach to receptor characterization, as opposed to radioligand binding studies or in vivo investigations. The results show that the dopamine receptor agonist apomorphine and three antagonists are unable to distinguish between the presynaptic, release-inhibiting dopamine autoreceptors and those postsynaptic dopamine receptors which, when activated, depress the release of acetylcholine. Although there are certainly more dopamine receptors in the caudate nucleus, these two physiologically important groups seem to be closely related.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6289174     DOI: 10.1016/0306-4522(82)90264-0

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  14 in total

Review 1.  Striatal dopamine in motor activation and reward-mediated learning: steps towards a unifying model.

Authors:  J Wickens
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 2.  Presynaptic regulation of dopaminergic transmission in the striatum.

Authors:  J Glowinski; A Chéramy; R Romo; L Barbeito
Journal:  Cell Mol Neurobiol       Date:  1988-03       Impact factor: 5.046

3.  Kinetic properties of the in vivo accumulation of 3H-(-)-N-n-propylnorapomorphine in mouse brain.

Authors:  S B Ross; D M Jackson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

4.  Endogenous adenosine as a modulator of hippocampal acetylcholine release.

Authors:  R Jackisch; H Strittmatter; L Kasakov; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-10       Impact factor: 3.000

5.  Is inhibition of striatal synaptosomal tyrosine hydroxylation by dopamine agonists a measure of dopamine autoreceptor function?

Authors:  C J Fowler; G Thorell; M Andersson; O Magnusson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

6.  Acetylcholine release in rat nucleus accumbens is regulated through dopamine D2-receptors.

Authors:  K Wedzony; N Limberger; L Späth; T Wichmann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-09       Impact factor: 3.000

Review 7.  Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

8.  Biochemical, behavioural, and endocrine effects of CK 204-933, a novel 8 beta-ergolene.

Authors:  R Markstein; A Enz; J M Vigouret; A Jaton; A Closse; U Briner; P Gull
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

9.  Further functional in vitro comparison of pre- and postsynaptic dopamine receptors in the rabbit caudate nucleus.

Authors:  K Starke; L Späth; J D Lang; C Adelung
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-08       Impact factor: 3.000

10.  Release of acetylcholine and its dopaminergic control in slices from striatal grafts in the ibotenic acid-lesioned rat striatum.

Authors:  T Wichmann; K Wictorin; A Björklund; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.